 SAN FRANCISCO, Nov. 18, 2020 GLOBE NEWSWIRE -- Olema Pharmaceuticals, Inc. Olema or Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of 19.00 per share. The gross proceeds to Olema Oncology from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be 209.0 million. All of the shares are being offered by Olema Oncology. In addition, Olema Oncology has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. 